-
The disruptive, proprietary technology developed by EVerZom offers a yield 100 times higher than traditional methods.
-
This innovation has just been tech-transferred and validated in a GMP-grade biomanufacturing environment.
-
This first clinical batch will enable EVerZom to initiate regulatory non-clinical studies of its first drug candidate EVerGelTM.
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
EXO-Harvest to launch breakthrough scalable fixed-bed bioreactor platform for MSC and EVs manufacturing
Gosselies, Belgium, July 15, 2024 – EXO-Harvest, an affiliate of convEyXO, is thrilled to announce the successful launch of its cutting-edge multi-scale bioreactor platform for adherent cells and extracellular vesicles (EVs) production, in partnership with IPRATECH. The platform is now fully operational, marking a significant milestone in joint efforts to advance biotechnological solutions through engineering excellence. [Read more…]
Takeda and Alloy Therapeutics to Co-Develop iPSC-Derived CAR-T and CAR-NK Products (iCAR-T and iCAR-NK)
TOKYO & BOSTON — Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies. [Read more…]
Cynata Introduces Critical Innovation into MSC Manufacturing
In the context of cell therapy, product innovation is the introduction of a cellular product that is new or has significantly improved characteristics or intended uses. Over the past decade, a great deal of attention has been given to cell therapy product innovation, as demonstrated by the thousands of cell therapy products that have now entered clinical trials worldwide.
In contrast, process innovation refers to the implementation of a new or significantly improved production or delivery method. In the context of cell therapy, process innovation has received much less attention from the marketplace. [Read more…]
FREE organoid and organ-on-chip TRAINING and TICKETS at WORD+2025!
We are excited to announce these latest organoid and organ-on-a-chip partnerships for training and publishing.
WORC.Community, the founders of WORD+2025, QMUL Centre for Predictive in vitro Models and the University of Bern are excited to announce a new Organoid and Organ-on-a-chip training partnership on day three of WORD+2025. The training is a series of interactive lectures in the main auditorium. You’ll learn about the latest techniques and key methods employed at both universities. In addition, there will also be demonstrations from key technologies used in their workflows. [Read more…]
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 144
- Next Page »